Press Release: Dupixent is the first and only biologic to achieve significant improvements in ...
Dupixent showed significant improvements in disease remission and symptoms in bullous pemphigoid, meeting primary and secondary endpoints, with five times more patients achieving remission compared to placebo. It's the first medicine to show a significant steroid-sparing effect and could be the first targeted treatment for BP in the U.S. and EU if approved.
Reference News
Dupixent showed significant improvements in disease remission and symptoms in bullous pemphigoid, meeting primary and secondary endpoints, with five times more patients achieving remission compared to placebo. It's the first medicine to show a significant steroid-sparing effect and could be the first targeted treatment for BP in the U.S. and EU if approved.
Dupixent showed significant improvements in disease remission and symptoms in bullous pemphigoid, meeting primary and secondary endpoints in a pivotal study. Five times more patients achieved sustained disease remission compared to placebo, and Dupixent demonstrated a significant steroid-sparing effect. If approved, it would be the first targeted treatment for BP in the U.S. and EU.